ABSTRACT Leo Sachs spent almost his entire scientific career in Israel, at the Weizmann Institute of Science, and became a worldwide renowned scientist for his pioneering studies in normal hematopoiesis, its breakdown in leukemia and the suppression of malignancy by inducing differentiation, thereby bypassing genetic defects that give rise to malignancy. The cell culture system he established in the early 1960s for the clonal development of normal hematopoietic cells, made it possible to discover the proteins that regulate the viability, proliferation and differentiation of different blood cell lineages, the molecular basis of normal hematopoiesis and the changes that drive leukemia. His studies established significant general concepts including: a) the value of a multi-gene cytokine network in regulating the viability, number and development of different cell types; b) the existence of alternative pathways that give flexibility to development in both normal and cancer cells; c) the response of some cancer cells to normal regulators of development; d) suppression of myeloid leukemia by inducing differentiation, bypassing malignancy-driving genetic defects; e) identification of chromosomes that control tumor suppression; f) discovering apoptosis as a major mechanism by which WT-p53 suppresses malignancy and g) the ability of hematopoietic cytokines to suppress apoptosis in both normal and leukemic cells. It is gratifying that Leo had the good fortune to witness his pioneering discoveries and ideas move from the basic science stage to effective clinical applications, augmenting normal hematopoiesis in patients with various hematopoietic deficiencies, in patients requiring hematopoietic stem cell transplantation and in the suppression of malignancy by inducing differentiation and apoptosis.
Introduction
Leo Sachs ( Fig. 1 ) was born in Leipzig, Germany in 1924. Fortunately, he emigrated in 1933 with his family from Nazi Germany to England where he grew up. Some years after his schooling, he decided to move to Israel. His original intention was to help found a kibbutz, and to prepare himself for this purpose he worked in England as a farm laborer, mainly milking cows. In 1948 he obtained a B.Sc. degree in agriculture and agricultural botany at the University of Wales in Bangor and in 1951 went on to obtain a Ph.D. degree studying plant genetics and cytogenetics at the Trinity College, Cambridge University. He then decided to change direction to work on cytogenetics and development in mammals, including humans, and he was appointed a Research Scientist in Genetics at the John Innes Institute, England, working on mammalian chromosomes. Upon arrival in Israel in 1952, he joined the Weizmann Institute of Science as a geneticist, where he was given for prenatal diagnosis of sex and for a general prenatal diagnosis of human diseases. Amniotic fluid cells from fetuses of different ages were collected by amniocentesis and were shown to contain sufficient numbers of well-preserved fetal cells, which could be used for prenatal diagnosis of sex (Serr et al., 1955; Danon et al., 1956; Sachs and Danon, 1956; Sachs et al., 1956b) and also of fetal blood group antigens (Sachs et al., 1956a) . As Leo suggested at the time ), this first ever method can be applied to prenatal diagnosis of other genetic properties of the fetus and is now widely used for prenatal diagnosis in pregnant women.
Encouraged by Dr. Berenblum to find his own way in science and with an ensured supply of mice provided to him to expand his activities, Leo conducted some experiments on the chromosomes (Sachs and Gallily, 1955) of tumors with different abilities to be transplanted. His interest in regulation of normal and abnormal development led him to realize that it would be advantageous to choose a broad approach and, therefore, he decided to try and develop some new experimental systems that could be used to study these processes. This pioneering kind of research would become a characteristic of Leo's studies throughout his scientific career, in his studies on Polyoma and SV40 tumor viruses, chemical carcinogenesis in vitro, chromosome changes and reversibility of malignancy (reviewed in Sachs, 1995) and control of normal hematopoiesis and its breakdown in leukemia, which will be described in the following sections. In 1960, he was promoted to Associate Professor and established the section of Genetics and Virology, and in 1962, he became a Full Professor and head of the Department of Genetics, a position he held until his retirement. In 1968 he was appointed the Otto Meyerhof Professor of Molecular Biology and between 1974 -1979 he served as the Dean of the Faculty of Biology. Throughout his scientific career Leo supervised and mentored many Ph.D. students, some of who became prominent scientists on their own. Leo continued his work until his passing in the Department of Molecular Genetics that was created by the merger of the Genetics and Virology Departments in 1979.
Leo will always be remembered by the scientific communities in Israel and the world for his pioneering studies in several areas, most notably in normal hematopoiesis and leukemia, for which he received many awards including the Israel Prize for Natural 
Hematopoiesis and leukemia
It became clear to Leo that in order to study the development of normal and tumor cells, it was necessary to develop cell culture systems in which cells could be cloned and made to differentiate into unique cell lineages. He decided to use hematopoietic cells that give rise to blood cells of different lineages throughout the life of an individual. Mouse leukemia originating from different cell lineages induced by viruses and other agents could also be obtained, so it was possible to study in vitro the development in clones of normal hematopoietic as well as leukemic cells. He could also study the effects of infection of normal cells with leukemia viruses. The first viruses he used were the Moloney and Rauscher viruses. Since neither the normal hematopoietic nor the leukemic cells survived in the standard cell culture medium in vitro, he used feeder layers of different types of mouse cells as possible sources of factors that the hematopoietic cells may require. This procedure worked out well both for leukemic (Ginsburg and Sachs, 1961 a,b) and normal hematopoietic cells (Ginsburg and Sachs, 1963; Pluznik and Sachs, 1965 ). Leo's analysis of the molecular control of normal hematopoiesis therefore began with the development of a cell culture system for the cloning and clonal differentiation of different types of normal hematopoietic cells (Ginsburg and Sachs, 1963) . This cell culture system made 
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it possible to discover a family of cytokines that regulate cell viability, multiplication, and differentiation of different hematopoietic cell lineages, to analyze the origin of hematological diseases, and to identify ways of treating these diseases with normal cytokines.
Establishing the first in vitro system for clonal development of normal hematopoietic cells
In the cell culture system that was developed, normal cells from mouse blood-forming tissues were first cultured with feeder layers of other cell types, such as normal embryo fibroblasts. These feeder layers were chosen as a possible source of cells that may produce regulatory molecules required for the cloning and differentiation of different hematopoietic cell lineages. The first such system, which used cells cultured in liquid medium (Ginsburg and Sachs, 1963) , showed that it was possible to obtain clones containing mast cells or granulocytes in various stages of differentiation. The cultures also showed differentiation to macrophages. To formulate his basic idea Leo wrote as the concluding sentence of this 1963 paper "The described cultures thus seem to offer a useful system for a quantitative kinetic approach to hematopoietic cell formation and for experimental studies on the mechanism and regulation of hematopoietic cell differentiation" (Ginsburg and Sachs, 1963) . The mast cell clones described above were obtained from cultures of thymus and the granulocyte clones from cultures of spleen. Infection of the thymus with Moloney virus and of the spleen with Rauscher virus increased the number of mast cells and granulocytes, respectively, indicating that this virus infection enhanced cell survival and/or multiplication (Ginsburg and Sachs, 1963) . In vivo experiments with the Rauscher virus showed that the virus that infected nucleated erythroid cells could be assayed and cloned by a spleen colony-forming assay (Pluznik and Sachs, 1964) . The culture system using feeder layers was then applied to the cloning of different cell lineages in semisolid medium containing agar (Pluznik and Sachs, 1965) , which made it simpler to distinguish and isolate separate clones and was then also used by others (Bradley and Metcalf, 1966) . Analysis of the first types of clones obtained in agar showed clones containing macrophages, granulocytes, or both macrophages and granulocytes in various stages of differentiation. The macrophage clones in agar contained many metachromatic granules, giving them an apparent morphological resemblance to mast cells (Pluznik and Sachs, 1965; Ichikawa et al., 1966) . However, these metachromatic granules were not observed when the cells were cloned in methylcellulose (Ichikawa et al., 1966) , and electron microscopy revealed that these "mast" cells in agar colonies were in fact macrophages that had phagocytized agar (Lagunoff et al., 1966) . The experiments also showed that hematopoietic cell colonies grown in vitro can originate from single cells (Ginsburg and Sachs, 1963; Pluznik and Sachs, 1966; Paran and Sachs, 1969) and are therefore bona fide cell-clones. This agar or methylcellulose colony-forming assay was then applied to cloning and clonal differentiation of normal human macrophages and granulocytes (Paran et al., 1970; Pike and Robinson, 1970 ) and other blood cell lineages including erythroid cells (Stephenson et al., 1971) , B-lymphocytes (Metcalf et al., 1975) , T-lymphocytes Gerassi and Sachs, 1976) and megakaryocytes (Freedman et al., 1981) .
Discovery of colony-stimulating factors and differentiationinducing factors
When hematopoietic cells were cloned in soft agar, a harder agar layer was placed between the feeder layer cells and the hematopoietic cells seeded for cloning. This procedure revealed that the inducer(s) required for the formation of macrophage and granulocyte clones were secreted by the feeder layer cells and diffused through the agar (Pluznik and Sachs, 1965) . This finding led to the discovery that the inducers required for the formation of macrophage and granulocyte clones are present in the conditioned medium produced by the feeder cells (Ichikawa et al., 1966; (SEBD) in Leioa, Spain, (1996) . . These inducers were found in the conditioned medium from various types of normal and malignant cells (reviewed in Sachs, 1974) , which were then used to purify the different inducers (Landau and Sachs, 1971; Burgess et al., 1977; Stanley and Heard, 1977; Lipton and Sachs, 1981; Ihle et al., 1982) . A similar approach was later used to identify the protein inducers for cloning of T-lymphocytes (Mier and Gallo, 1980) and B-lymphocytes (reviewed in Hirano et al., 1990) . When cells were washed at various times after initiating the induction of clones, there was no further development of either macrophage or granulocyte clones unless the inducer was re-added . The development of clones with differentiated cells thus requires both an initial and a continued supply of inducer.
In cells belonging to the myeloid cell lineages, several different proteins that induce cell proliferation giving rise to colonies (colonyinducing proteins) have been identified (reviewed in Sachs, , 1987 Sachs, a,b, 1990 Sachs, , 1992 Sachs, , 1995 . The same proteins were given different names. After their discovery in conditioned medium Ichikawa et al., 1966) , the first inducer identified was given the name "Mashran gm" based on the Hebrew word meaning "to send forth" with the initials for granulocytes and macrophages (Ichikawa et al., 1967) . This and other colony-inducing proteins were then renamed as macrophage and granulocyte inducers (MGI) (Landau and Sachs, 1971 ) and MGI-type 1 (MGI-1) (Lotem et al., 1980) and are now collectively called colony-stimulating factors (CSFs) (reviewed in Metcalf, 1985; Sachs, 1987b; Witte, 1990) . Of the different CSFs identified, M-CSF induces the development of clones with macrophages, G-CSF clones with granulocytes, GM-CSF clones with granulocytes, macrophages, or both macrophages and granulocytes and stem cell factor (SCF) clones with blast cells and granulocytes at different stages of maturation. Another factor called interleukin-3 (IL-3) (Ihle et al., 1982) had CSF activity that induced clones with macrophages, granulocytes, eosinophils, mast cells, erythroid cells, or megakaryocytes. All CSFs induce cell viability and proliferation (reviewed in Sachs, 1987b Sachs, , 1990 Sachs, , 1992 Sachs and Lotem, 1993; Sachs 1995) of myeloid precursor cells and enhance the functional activity of mature cells (reviewed in Metcalf, 1985) . Cloning of human and mouse CSF genes revealed that distinct genes encode each of the CSFs (reviewed in Clark and Kamen, 1987; Lennartsson and Ronnstrand, 2012) .
It seemed to Leo and his colleagues quite unlikely that a CSF that induces cell proliferation can also simultaneously induce terminal cell differentiation that involves arresting cell proliferation in mature cells. Therefore, they looked for a protein that acts as a myeloid cell-differentiation inducer but does not have significant CSF activity. When such a protein was discovered, it was given the name macrophage and granulocyte inducer-type 2 (MGI-2) (Lotem et al., 1980; and reviewed in Sachs, 1987 and reviewed in Sachs, a,b, 1990 and reviewed in Sachs, , 1995 . The amino acid sequence of a 22 amino acid CNBr-cleaved peptide derived from purified mouse MGI-2 protein (Shabo et al., 1988) proved identical to that of recombinant mouse IL-6 . Moreover, recombinant mouse IL-6 possessed myeloid cell differentiation-inducing activity that could be inhibited by monoclonal anti-MGI-2 antibody, showing that the myeloid differentiation-inducing protein MGI-2 is identical to IL-6 (Shabo et al., 1988) . Studies on myeloid leukemic cells have identified other differentiation-inducing proteins called D-factor and differentiationinducing factor (DIF) (reviewed in Sachs, 1990) . D-factor has also been called human interleukin for DA cells (HILDA) and leukemia inhibiting factor (LIF) (Moreau et al., 1988) , and DIF was found to be a form of tumor necrosis factor (TNF) (reviewed in Sachs, 1990) . Whereas IL-6 can induce viability and differentiation of normal myeloid precursors, LIF and TNF, which induce differentiation in certain clones of myeloid leukemic cells, do not induce viability or differentiation of normal myeloid cells (reviewed in Sachs, 1990) .
Hematopoietic cytokine network
The existence of a family of hematopoietic cytokines raised the question whether these cytokines interact with each other. Leo found that all CSFs induce the production of IL-6 in normal myeloid precursor cells Sachs, 1982, 1983) , which can then induce these cells to differentiate to macrophages, granulocytes, or megakaryocytes (Sachs, , 1987 (Sachs, a,b, 1990 . This induction of a differentiation factor such as IL-6 by a CSF growth factor can thus serve as an effective mechanism to couple growth and differentiation (Fig. 3 ). IL-6 may switch on other, yet unidentified, factors that may be required to determine the specificity of the terminally differentiated cell type. Thus, one Fig. 3 (left) . Induction of differentiation-inducing proteins by growth-inducing proteins serves as a coupling mechanism in normal myeloid cell development. Fig. 4 (right) . Cytokine network of interactions in myeloid cell development.
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have effects similar to these cytokines? Leo showed that there are human and murine myeloid leukemic cells that can be induced to differentiate to mature granulocytes and macrophages by media containing normal hematopoietic cytokines (Paran el al., 1970; Fibach et al., 1972) (Fig. 5) . The clones of myeloid leukemic cells that could be induced to differentiate to mature macrophages or granulocytes by a normal myeloid differentiation-inducing cytokine were designated D+ clones (D for differentiation) (Fibach et al., 1973) . The temporal sequence of acquired differentiation-associated functions in these D+ leukemic cells was the same as in normal myeloid precursor cells (Lotem and Sachs, 1977) . Importantly, the mature cells that have developed from these leukemic clones stopped dividing, behaving like normal mature cells (Fibach, et al., 1973; Sachs, 1974, 1975; Lotem and Sachs, 1977) . These cells were no longer malignant in vivo (Fibach and Sachs, 1975) . In addition to these D+ clones that can be induced to terminally differentiate by IL-6 and to partially differentiate with G-CSF, Leo found D+ clones from another myeloid leukemia that can be induced to differentiate with GM-CSF or IL-3 but not with IL-6 or G-CSF (reviewed in Sachs, 1987 Sachs, a,b, 1990 .
The D+ clones that respond to these CSFs are presumably induced by the CSFs to produce appropriate endogenous differentiation inducer(s) other than IL-6. The D+ leukemic cells that respond to IL-6 can also be induced to differentiate by IL-la and IL-lb, mediated by the endogenous production of IL-6 (reviewed in Sachs, 1990) .
Subsequent studies have shown that differentiation of D+ myeloid leukemic cells to mature non-dividing cells can be induced not only by adding cytokines in culture, but also occurs in vivo (Lotem and Sachs, 1978 . However, when several thousand of these leukemic cells were injected into adult syngeneic mice they grew progressively and eventually killed the host, presumably because the amount of differentiation inducers in the body was too low to overcome the overload of leukemic cells failing to induce terminal differentiation of all leukemic cells. When sufficient amounts of differentiation-inducing protein or compounds that induce their production by cells in the body were injected, the development of of the concepts that emerged from Leo's studies on hematopoiesis is that the different hematopoietic cytokines function in a network of interactions (Lotem et al., 1991b and reviewed in Sachs, 1990 , 1995 Sachs and Lotem, 1994) (Fig. 4) .
Production of specific cell types has to be induced when new cells are required and has to stop when sufficient cells have been produced. This requires an appropriate balance between inducers and inhibitors of development, which is achieved by cytokines that can function as inhibitors, such as TNF and transforming growthfactor b1 (TGFb1), which can selectively inhibit the activity and production of some CSFs and ILs (Fig.  4) . This network and the pleiotropic effects of its cytokines such as IL-6, IL-1, TNF and TGFb1 outside the hematopoietic system (reviewed in Sachs, 1995) must to be taken into account in the clinical use of these cytokines. What can be therapeutically effective may be due to the direct action of an injected cytokine or to an indirect effect due to other cytokines that are switched on in vivo. A network of interactions allows considerable flexibility depending on which part of the network is activated. It also allows a ready amplification of response to a particular stimulus such as bacterial lipopolysaccharide released during certain infections (reviewed in Sachs, 1990 ). This amplification can occur both by auto-regulation and by trans-regulation of hematopoietic cytokine genes (Sachs, 1990 ) and also involves cytokine-induced up-regulation of different cytokine receptors Sachs, 1986, 1989) . These cytokineinduced changes during differentiation are mediated by induction of sustained levels of transcription factors that can regulate and maintain gene expression in the differentiation program (Shabo et al., 1990) . In addition to the flexibility of this network in response to different infections, it may also contribute to the stability of the hematopoietic system.
Normal cytokines and other compounds that control differentiation of myeloid leukemia cells
The next two major questions Leo asked were: (1) Can the cytokines that control normal hematopoiesis also control the behavior of leukemic cells? (2) Are there are other compounds that may 
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leukemia by these D+ leukemic cells could be inhibited and mice survival was prolonged (Lotem and Sachs, 1981 and reviewed in Sachs, 1987 Sachs, a,b, 1990 . Induction of differentiation of D+ clones in vivo can occur either directly by the cytokine to which the cells respond in vitro, or by an indirect mechanism that involves induction of the appropriate differentiation-inducing protein either by the same cells or by other cells in the body . Remarkably, when these D+ myeloid leukemic cells were injected into mouse fetuses, they were shown to participate in normal hematopoietic cell differentiation to mature granulocytes and macrophages in apparently healthy adult animals that did not develop leukemia (Gootwine el al., 1982; Webb et al., 1984) . The D+ myeloid leukemic cells have an abnormal chromosome composition (Fibach et al., 1973; Hayashi et al., 1974; Azumi and Sachs, 1977 ), yet suppression of malignancy in these cells during differentiation was not associated with regaining a normal diploid chromosome complement. Thus, the stopping of cell multiplication by inducing differentiation to mature cells bypasses genetic changes that produced the malignant phenotype (Sachs, 1987c) , such as loss of a requirement for a normal cytokine for viability and growth and a block in the ability of growth inducer to promote production of a differentiation inducer.
The study of different clones of myeloid leukemic cells has shown that in addition to D+ clones there are differentiation-defective (D-) clones (Paran et al., 1970; Fibach et al., 1973) . A variety of D-clones have been used to genetically dissect the differentiation program and analyze the differentiation blocks in leukemic cells (reviewed in Sachs, 1995) . Some D-clones are induced by a normal myeloid differentiation-inducing cytokine to an intermediate stage of differentiation, which then slows down cell proliferation, while other D-clones could not be induced to differentiate even to this intermediate stage. These observations indicated that there are different blocks in the differentiation program of myeloid leukemic clones (Lotem and Sachs, 1974) . The fact that a normal differentiation inducer can induce differentiation to mature non-dividing cells in the D+ clones, has led Leo to suggest that D+ clones represent early stages of leukemia development and that the appearance of D-clones may represent later stages in the progression of malignancy (reviewed in Sachs, 1987 Sachs, a,b, 1990 . He then went on to show that even such D-cells can be induced to differentiate by other compounds, either singly or in combination, that can induce the differentiation program by alternative pathways (reviewed in Sachs, 1982, l987a) . The stopping of cell proliferation by inducing differentiation via these alternative pathways bypasses the genetic changes that inhibit response to the normal differentiation inducer (reviewed in Sachs, 1987 Sachs, a,b, 1990 .
Leo's studies on the genetic changes in various myeloid leukemic D-clones have shown that differentiation defectiveness may be due to aberrant expression of a homeobox gene such as Hox2.4/ Hoxb8 (Blatt et al., 1988; Ben-David et al., 1991) . Forced expression of Hoxb8 in D+ myeloid leukemic cells inhibits specific pathways of myeloid cell differentiation (Blatt et al., 1992) . Moreover, it was subsequently shown that introduction of Hoxb8 into normal bone marrow cells enhances the self-renewal of myeloid progenitors and is sufficient for their progression to myeloid leukemia in vivo, which is associated with acquisition of mutations conferring autocrine production of IL-3 (Perkins and Cory, 1993) . More recent studies have shown that deregulation of other Hox genes by chromosomal translocations also occurs in human leukemia (reviewed in Rice and Licht, 2007) .
In his studies with a variety of chemicals, other than the normal hematopoietic cytokines, Leo found that many compounds could induce differentiation in D+ clones of myeloid leukemic cells. These include glucocorticoid hormones and chemicals used in cancer chemotherapy such as cytosine arabinoside, doxorubicin, methotrexate and even irradiation. At high doses, irradiation and these chemotherapeutic compounds kill cells by inducing apoptosis, whereas at low doses they induce differentiation. Not all these compounds are equally active on the same leukemic clone (reviewed in Sachs, 1978 Sachs, , 1982 . In addition, other compounds that can induce differentiation in myeloid leukemic cells include insulin, bacterial lipopolysaccharide, certain plant lectins, tumor-promoting phorbol esters (reviewed in Sachs, 1978 Sachs, , 1982 Sachs, , 1987a and retinoic acid (Breitmann et al., 1980 and reviewed in Degos, 1992 . Of special interest is the finding that a variety of chemicals or their combination can also induce differentiation in some D-clones (reviewed in Sachs, 1982) . These results indicate that besides normal myeloid cytokines, other physiological compounds including steroid hormones, insulin, and retinoic acid can also induce differentiation of myeloid leukemic cells. These findings raise the possibility that in fact all D-myeloid leukemic cells, which are no longer susceptible to the normal hematopoietic cytokines alone, can be induced to differentiate by the appropriate combination of other compounds. Thus, Leo's experiments with myeloid leukemic cells have shown that there are different pathways of gene expression for inducing differentiation and that genetic changes which inhibit induction of differentiation by one compound need not affect differentiation induced by another compound through alternative pathways.
Cytokines and control of programmed cell death
Normal myeloid precursor cells depend on hematopoietic cytokines for viability, proliferation and differentiation (reviewed in Sachs, 1987 Sachs, a,b, 1990 Sachs and Lotem, 1993) . Withdrawal of these cytokines leads to cell death by apoptosis. The program for cell death in factor-deprived cells is present not only in normal myeloid precursor cells but also in more differentiated progeny including mature granulocytes and macrophages. Although viability factors such as the CSFs also induce growth, the viability and growth processes are separately regulated (reviewed in Sachs and Lotem, 1993) . Cancer cells, like their normal counterparts, are not immortal. Even tumor cell lines that have been sub-cultured for years contain cells that will eventually die by apoptosis. The ability to sub-culture these cell lines for long periods of time is maintained because more cells survive and divide than those that die. While most myeloid leukemic cells initially maintain a normal requirement for hematopoietic cytokines for viability and growth, certain myeloid leukemic clones have become independent on these factors and therefore do not require an exogenously added cytokine for cell viability and growth. Yet, even in such factor-independent leukemic cells, the endogenous program for cell death is not lost and can be activated in different ways. Leo's studies have shown that induction of differentiation in D+ leukemic cells by IL-6 induces a viability-factor dependent state in the differentiating cells, so that the cells undergo apoptosis following withdrawal of IL-6 Lotem and Sachs, 1982 , 1983 . This regaining of the normal program for cell death in the IL-6-induced leukemic cells occurs before their terminal differentiation and the differentiating cells can be rescued from apoptosis and continue to divide by re-adding IL-6 or replacing it with IL-3, M-CSF, G-CSF or IL-1 . Induction of apoptosis in differentiating myeloid leukemic cells deprived of viability factors thus constitutes activation of a normal physiological process that can potentially be used to suppress leukemia.
Cancer cells can be induced to undergo apoptotic cell death by different cytotoxic agents including chemotherapeutic compounds and irradiation, which is the basis for cancer therapy. Leo's studies with murine myeloid leukemic cell lines and primary leukemic cells from human acute myeloid leukemia patients (Kaplinsky et al., 1996) have shown that this cytotoxic agents induced apoptosis can also be inhibited by different CSFs and ILs acting as viability factors. Studies by others have also shown that various cytokines can inhibit cytotoxic agents induced apoptosis in other cells types such as T-lymphocytes and neurons (reviewed in Lotem and Sachs, 1999) . Using growth-factor independent myeloid leukemic cells that lack expression of the tumor suppressor p53, Leo and colleagues have shown that transfection with a plasmid encoding a temperature-sensitive mutant p53 (Ala to Val change at position 135), induces apoptosis when cells are shifted from 37.5°C to 32.5°C, at which the Val 135 mutant protein assumes wild-type (WT) p53 conformation and activity (Yonish-Rouach et al., 1991) . This WT-p53-induced apoptosis was not associated with differentiation induction but was effectively inhibited by IL-6 (Yonish-Rouach et al., 1991) , suggesting that p53-mediated apoptosis in these myeloid leukemic cells is in fact a normal physiological process. Subsequent experiments using p53-deficient mice have confirmed that WT-p53 is physiologically involved in mediating apoptosis in normal myeloid precursors deprived of the appropriate cytokine concentration required for cell viability and also following DNA damage by g-irradiation (Lotem and Sachs, 1993a) . In addition, these experiments have also shown that g-irradiation induces apoptosis in normal thymocytes by a p53-dependent process and that there are also WT-p53-independent pathways of inducing apoptosis in these cells (Clarke et al., 1993; Lotem and Sachs, 1993a; Lowe et al., 1993) . Leo's studies have also revealed that WT-p53-induced apoptosis in myeloid leukemic cells can be inhibited by antioxidants, protease inhibitors and calcium mobilizing compounds, the latter acting via activation of calcineurin, a calcium-calmodulin-dependent phosphatase (Lotem and Sachs, 1997 , 1999 (Fig. 6 ). Of particular interest is Leo's finding that inhibition of p53-induced apoptosis by IL-6 and calcium mobilizing compounds is not due to a general block of the wild-type p53-induced changes in gene expression but rather is mediated by induction of anti-apoptotic genes such as Bcl3, Stat3 and Spp1 , that override the p53-induced apoptotic program (Lotem et al., 2003) .
The induction of apoptosis in myeloid leukemic cells by various cytotoxic agents, including those used in cancer therapy , is enhanced by overexpression of c-myc (Lotem and Sachs, 1993b) . Conversely, the mutant p53 (Lotem and Sachs, 1993b) and bcl-2 oncogenes (reviewed in Korsmeyer, 1992) suppress the enhancing effect of deregulated c-myc on apoptosis and thus allow c-myc-mediated induction of cell proliferation and inhibition of differentiation (Lotem and Sachs, 1993b) . The suppression of cell death by mutant p53 and bcl-2 increases the probability of developing tumors. Treatments that down-regulate the expression or activity of mutant p53 and Bcl-2 in tumor cells can thus be useful to increase susceptibility of tumors to cytotoxic cancer therapy (Sachs and Lotem, 1993; Lotem and Sachs, 1994) . Leo showed that Bcl-2 protein expression was strongly and rapidly reduced in myeloid leukemic cells by treatment with cytokines such as IL-6 and G-CSF and by the steroid hormone dexamethasone Sachs, 1993b, 1994) and in human acute promyelocytic leukemic cells by all-trans-retinoic acid (Chomienne et al., 1992) . The cytokine-mediated decrease in Bcl-2 expression enhanced leukemic cell susceptibility to apoptosis induction by cancer chemotherapeutic compounds . Collectively, Leo's studies on the cytokine and gene regulation of apoptosis in normal and leukemic myeloid cells have shown that there are alternative pathways to apoptotic cell death, which can be useful to selectively control cell viability of cancer cells and thus may have important implications in cancer therapy (Sachs and Lotem, 1993) .
Therapeutic use of hematopoietic cytokines
The identification of myeloid cell regulatory cytokines has led Leo to suggest novel possibilities for therapy (reviewed in Sachs, 1978 Sachs, , 1987 Sachs, a,b, 1990 Sachs, , 1995 Sachs, , 1996 . Directly injecting these cytokines or inducing their production in vivo by other compounds (Fibach and Sachs, 1974; Lotem and Sachs, 1978 could elevate their in vivo levels and thereby enhance myelopoiesis. The finding that apparently normal granulocyte development can be induced in culture of cells from patients with infantile genetic agranulocytosis (Paran et al., 1970; Barak et al., 1971 ) has led to promising clinical results with G-CSF in children with this genetic disease as well as in acquired idiopathic neutropenia and aplastic anemia patients (reviewed in Mehta et al., 2015) . Moreover, G-CSF and GM-CSF were also shown to be clinically effective treatments for irradiation, chemotherapy or immune suppressionassociated neutropenia (reviewed in Mehta et al., 2015) . Because of the important functions of mature cells, such as granulocytes and other myeloid cells, the increased CSF-mediated survival and function of mature cells can also be clinically helpful to patients with deficiencies in myeloid cell production, functions and viability (reviewed in Sachs, 1990) . Induction of apoptosis of cancer cells is the basis for most if not all cancer therapy regimens. As indicated in the previous section, hematopoietic cytokines including various CSFs, IL-6 and IL-1 can inhibit apoptosis of cancer cells induced by various cancer chemotherapy compounds and irradiation Sachs and Lotem, 1993) . The clinical use of cytokines to correct therapy-associated suppression of normal hematopoiesis should therefore be carefully timed to avoid protection of the malignant cells from the cytotoxic action of therapeutic compounds . The bone marrow contains hematopoietic stem cells (HSC) that can repopulate all hematopoietic lineages in lethally irradiated hosts (reviewed in Dzierzak et al., 1998; Weissman, 2000) , creating the basis for bone marrow transplantation. The finding that G-CSF and GM-CSF can enhance the migration of HSCs from bone marrow to peripheral blood (reviewed in Horsfall et al., 2000; Gazitt, 2001) , by decreasing the chemokine SDF-1 and increasing CXCR4 in bone marrow (Petit et al., 2002) , has simplified the procedure for HSC harvesting for transplantation into patients with immunodeficiency and in cancer patients following chemotherapy and irradiation.
Differentiation therapy: from hypothesis to practice
Failure to terminally differentiate together with enhanced viability and proliferation characterizes most, if not all, cancer cells of every origin. Whether the induction of differentiation could be a valid treatment strategy for cancer was hotly debated before the advent of differentiation therapy. Based on his discovery in the early 1970s that myeloid leukemic cells could be reprogrammed by various cytokines and other compounds to resume normal differentiation and to become non-dividing mature granulocytes or macrophages (reviewed in Sachs, 1978 Sachs, , 1987 Sachs, a,b, 1990 Sachs, , 1995 , Leo hypothesized that treatment with agents that induce cancer cells to complete differentiation could be a potential therapeutic option for patients with cancer (Sachs, 1978) . In the early 1980s, Breitman and colleagues showed that retinoic acid, a derivative of vitamin A, could induce human promyelocytic cells of the HL-60 leukemic cell line (Breitman et al., 1980) and primary cells from human acute promyeloicytic leukemia (APL) patients (Breitman et al., 1981) to terminally differentiate in vitro to mature neutrophil granulocytes. Subsequently, a clinical trial showed that all-trans RA (ATRA) produced remarkable complete remission in more than 95% of APL patients with evidence for leukemic cell morphological maturation in all patients (Huang et al., 1988) . Currently, ATRA combined with anthracycline-based chemotherapy can achieve complete remission in 90%-95% of APL patients and overall 5-year disease-free survival in up to 75% of patients (Zhou et al., 2005) . Both ATRA and arsenic trioxide, another differentiation inducing and clinically effective compound in APL, act by inducing degradation of the PML-RARa oncogenic fusion protein that drives APL development, allowing the cells to regain normal differentiation and undergo apoptosis and thus achieve complete remissions in vivo (Zhu et al., 2001; Zhou et al., 2005) .
